{"id":"NCT03998163","sponsor":"Cara Therapeutics, Inc.","briefTitle":"CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus","officialTitle":"An Open-Label, Multicenter Study to Evaluate the Safety and Effectiveness of Intravenous CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-05-06","primaryCompletion":"2020-02-26","completion":"2020-03-06","firstPosted":"2019-06-26","resultsPosted":"2021-10-15","lastUpdate":"2021-10-15"},"enrollment":222,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Uremic Pruritus"],"interventions":[{"type":"DRUG","name":"CR845 0.5 mcg/kg","otherNames":["CR845","Difelikefalin"]}],"arms":[{"label":"CR845 0.5mcg/kg","type":"EXPERIMENTAL"}],"summary":"This is a multicenter, open-label study to evaluate the safety and effectiveness of intravenous (IV) CR845 at a dose of 0.5 mcg/kg administered after each dialysis session. The study includes an up to 12-week Treatment Period.","primaryOutcome":{"measure":"Number of Participants With AEs.","timeFrame":"Up to Follow-Up Visit (Week 13-14)","effectByArm":[{"arm":"CR845 0.5mcg/kg","deltaMin":143,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":47,"countries":["United States","Czechia","Hungary","Poland"]},"refs":{"pmids":["39037824","38196014","37968132","36185706","36039153"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":45,"n":222},"commonTop":["Diarrhoea"]}}